AREXVY 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0006/G 
This was an application for a group of variations. 
01/02/2024 
SmPC 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IB/0003/G 
This was an application for a group of variations. 
19/12/2023 
n/a 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.4.z - Change in the batch size (including batch 
size ranges) of the finished product - Other variation 
IG/1677 
B.III.2.z - Change to comply with Ph. Eur. or with a 
27/11/2023 
n/a 
national pharmacopoeia of a Member State - Other 
variation 
IB/0001 
B.II.d.2.f - Change in test procedure for the finished 
07/07/2023 
n/a 
product - To reflect compliance with the Ph. Eur. and 
remove reference to the outdated internal test 
method and test method number 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
